Retatrutide has shown the potential to reduce hepatic steatosis, accompanied by changes in adiponectin, leptin, triglycerides, and FGF21 levels—factors closely associated with lipid metabolism and insulin sensitivity. The gene discussed is INS; the disease is Hepatic steatosis.